Alexion Pharmaceuticals
Listing Websites about Alexion Pharmaceuticals
Alexion Pharmaceuticals - Wikipedia
(3 days ago) Alexion Pharmaceuticals is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. It became an independent subsidiary of AstraZeneca in 2021. Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to trea…
Url: Visit Now
Category: Pharmaceutical Detail Drugs
AstraZeneca to acquire Alexion, accelerating the …
(6 days ago) WebAstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders …
Url: Visit Now
Category: Pharmaceutical Detail Drugs
Acquisition of Alexion completed - AstraZeneca
(8 days ago) WebThe Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as …
Url: Visit Now
Category: Health Detail Drugs
Alexion Pharmaceuticals, Inc. LinkedIn
(7 days ago) WebAlexion Pharmaceuticals, Inc. 265,885 followers. 4w. For the past 30 years, Alexion has been among the first to tackle scientific challenges for #rarediseases by following the science and leading
Url: Visit Now
Category: Pharmaceutical Detail Drugs
Alexion, AstraZeneca Rare Disease, Completes Acquisition of …
(5 days ago) WebAlexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion …
Url: Visit Now
Category: Health Detail Drugs
Alexion Pharmaceuticals Company Overview & News
(7 days ago) WebAlexion Pharmaceuticals. Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and
Url: Visit Now
Category: Pharmaceutical Detail Drugs
Alexion Careers Job Search Results
(5 days ago) WebAstraZeneca completed its acquisition of Alexion, marking the creation of Alexion, AstraZeneca Rare Disease. If you’re interested in career opportunities with AstraZeneca, …
Url: Visit Now
Category: Health Detail Drugs
Catalent, Inc - Financials - Annual Reports
(8 days ago) WebInvestor Relations Dept Catalent, Inc. 14 Schoolhouse Road Somerset, NJ 08873 Phone: +1 732 537 6325 Fax: +1 732 537 5932 Mail: [email protected]
Url: Visit Now
Category: Health Detail Drugs
Amneal Pharmaceuticals LLC Issues Voluntary Nationwide Recall of
(2 days ago) WebAmneal Pharmaceuticals LLC Bridgewater, New Jersey (Amneal), is voluntarily recalling all lots of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, …
Url: Visit Now
Category: Pharmaceutical Detail Drugs
Organon Inc. West Orange, NJ - Macrae's Blue Book
(5 days ago) WebOrganon Inc. Products: Prescription pharmaceuticals Biochemical and biotechnology production, Rubber production, Plastic and chemical industries, Petrochemical and …
Url: Visit Now
Category: Pharmaceutical Detail Drugs
› Alaska medical licensing board
› Cms gov medicare provider portal
› What does part b medicare cover
› Biomedical engineer data science jobs
Recently Searched› Northridge hospital medical center az
› Health care disparity among elderly
› Drug acronyms and abbreviations
› Fda generic drug approval list
› Best colleges for medicine undergrad
› Drug co pay assistance program
FAQ about Alexion Pharmaceuticals
Where is Alexion Pharmaceuticals located?
Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell, a physician at Yale New Haven Hospital and assistant professor of medicine and pathology at Yale School of Medicine. [3] [4] In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. [5] [6]
What can Alexion do for AstraZeneca?
We look forward to also applying Alexion’s complement-biology platform across areas of AstraZeneca’s broader early stage pipeline and, significantly, to the extraordinary opportunity to extend existing and future rare disease medicines to patients in many countries where AstraZeneca already has a strong presence.”
How much consideration was paid to the Alexion shareholders?
The total consideration paid to the Alexion shareholders was approximately $13.3bn in cash and 236,321,411 new AstraZeneca shares (approximately 94% of which will be represented by new AstraZeneca American Depositary Shares (ADSs)).
Why should you invest in Alexion?
We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world.